TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›VOR›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Vor Biopharma Inc. (VOR) financials

Income statement

Vor Biopharma Inc. (VOR) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$43.4M-$69.0M-$93.4M-$126M-$121M-$372M
Net income-$43.3M-$68.9M-$92.1M-$118M-$117M-$696M
EPS (diluted)-$230.57-$2.10-$2.33-$1.75-$34.03-$70.50

Cash flow

Vor Biopharma Inc. (VOR) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$36.3M-$69.1M-$85.1M-$100M-$99.7M-$143M
Capital expenditures$4.16M$3.89M$8.46M$1.07M$229K$941K
Free cash flow-$40.5M-$73.0M-$93.6M-$101M-$99.9M-$144M
Dividends paid$0.00$0.00$0.00$0.00$0.00$0.00

Balance sheet

Vor Biopharma Inc. (VOR) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$48.5M$120M$57.7M$31.4M$81.9M$396M
Total assets$75.9M$243M$299M$198M$143M$464M
Total liabilities$27.6M$26.3M$48.8M$47.4M$46.2M$628M
Shareholders' equity-$59.1M$216M$251M$151M$96.7M-$164M
Retained earnings-$61.2M-$130M-$222M-$340M-$457M-$1.15B
Shares (wtd avg diluted)505K33.4M39.6M67.2M3.44M9.87M

Every figure is extracted from Vor Biopharma Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Vor Biopharma Inc.'s free cash flow?
-$144M in FY2025 (operating cash flow -$143M minus $941K of capital expenditures), from the SEC cash-flow statement.
Does VOR pay a dividend?
Vor Biopharma Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full VOR analysis — verdict, score & filings →Is VOR a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.